Search clinical trials for: SAR443765

Total 14 results

Sanofi

Recruiting

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Moderatetosevere Asthma. (AIRPHRODITE)

Asthma

Korea, Republic of, Chile, Turkey, Japan, China, Israel, United States, Argentina
Sanofi

Recruiting

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

Dermatitis Atopic

United States, Japan
Sanofi

Recruiting

A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

Belgium, Argentina, Poland, United States, United Kingdom, Bulgaria
Sanofi

Recruiting

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study

Chronic Rhinosinusitis With Nasal Polyps

United States
Kadmon, a Sanofi Company

Completed

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

Immune System Disorder (Healthy Volunteer)

United States
Kadmon, a Sanofi Company

Completed

A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

Immune System Disorder (Healthy Volunteer)

United States
Sanofi

Recruiting

A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies

Chronic Graft Versus Host Disease

China
Kadmon, a Sanofi Company

Recruiting

Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

Chronic Graft Versus Host Disease

United States
Kadmon, a Sanofi Company

Completed

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

Immune System Disorder (Healthy Volunteer)

United States
Kadmon, a Sanofi Company

Completed

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

Immune System Disorder (Healthy Volunteers)

United States
Sanofi

Completed

First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants

Asthma

Germany, United Kingdom
Sanofi

Recruiting

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. (ROCKnrol-1)

Chronic Graft Versus Host Disease

Australia, China, Canada, Sweden, France, Turkey, United Kingdom, Korea, Republic of, Germany, Israel, Italy, United States, Czechia, Netherlands, Belgium, Denmark, Spain, Argentina, Brazil, Austria, Hong Kong, Poland, Portugal, Greece
Sanofi

Recruiting

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (AIRLYMPUS)

Asthma

United States, Belgium, Spain, Sweden, Chile, Italy, United Kingdom, Argentina, Hungary, Canada, Turkey, Israel, Taiwan, China, Germany, Poland, Romania, Denmark, France
Sanofi

Recruiting

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Plasma Cell Myeloma Refractory

France, Australia, Norway, Portugal, Korea, Republic of, Greece, Germany, Israel, United States, Puerto Rico, Italy

3

Subscribe